Clinical trials: Tamoxifen
Breast Cancer
Premenopausal Patient With Hormone Responsive, HER2 Negative, Lymph Node Positive Breast Cancer
The purpose of this study is to compare neo-adjuvant therapy of cytotoxic chemotherapy versus GnRHa with tamoxifen , of response rate(RR) in patients of hormone responsive and HER2 negative, lymph node positive, primary breast…
- Trial name
- NEST (NCT01622361)
- Testing
- Adriamycin+Cyclophosphamide>Docetaxel, GnRHa with Tamoxifen
- Where
- South Korea
- Volunteers
- 290 people
- Sponsor
- Asan Medical Center
Breast Cancer
Trastuzumab and Chemotherapy Followed by Surgery and Combination Chemotherapy in Treating Women With Locally Advanced Breast Cancer
RATIONALE: Monoclonal antibodies such as trastuzumab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.
- Trial name
- NCT00009997
- Testing
- trastuzumab, cyclophosphamide, doxorubicin hydrochloride
- Where
- United States
- Sponsor
- NYU Langone Health
Breast Cancer, Breast Cancer Stage II
Assessing the Response Rate of Neo-adjuvant Paclitaxel (Taxol) in Nigerian Women With Breast Cancer
This is a two-stage phase II study with a single arm design. It will be conducted in women with breast cancer with stages IIA to IIIC (defined by AJCC 2009 classification) of all histological subtypes.
- Conditions
- Breast Cancer, Breast Cancer Stage II, Breast Cancer Stage III
- Trial name
- NCT03058939
- Testing
- Paclitaxel, Perjeta, Herceptin SC
- Where
- Nigeria
- Sponsor
- University of Chicago
Advanced Breast Cancer
Dalpiciclib With Endocrine Therapy for Advanced Breast Cancer After CDK4/6 Inhibitor Failure (DAWNA-FES)
CDK4/6 inhibitors are currently the standard treatment for female breast cancer patients with HR+ tumors. However, there is no established standard treatment for patients who experience treatment failure with CDK4/6 inhibitors.
- Trial name
- NCT05861830
- Testing
- The combination of Dalpiciclib with physician-selected endocrine therapy, Chemotherapy selected by the physician
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Peking Union Medical College Hospital
Desmoid Tumor
Toremifene in Treating Patients With Desmoid Tumors
RATIONALE: Estrogen can stimulate the growth of cancer cells. Hormone therapy using toremifene may fight the growth of desmoid tumors by reducing the production of estrogen.
- Trial name
- NCT00002595
- Testing
- toremifene, conventional surgery
- Where
- United States
- Volunteers
- 72 people
- Sponsor
- Advocate Lutheran General Hospital
Breast Cancer
Letrozole or Tamoxifen in Treating Postmenopausal Women With Breast Cancer
RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using letrozole may fight breast cancer by reducing the production of estrogen.
- Trial name
- BIG 1-98 (NCT00004205)
- Testing
- letrozole, tamoxifen citrate
- Where
- 3 sites in Denmark, France and 1 more
- Volunteers
- 8,028 people
- Sponsor
- ETOP IBCSG Partners Foundation
Breast Cancer
Tamoxifen Versus Anastrozole, Alone or in Combination With Zoledronic Acid
The primary objective is, first, the comparison of tamoxifen and anastrozole and, second, the comparison of zoledronate added to standard adjuvant therapy with controls according to disease-free survival (DFS) in premenopausal…
- Trial name
- NCT00295646
- Testing
- tamoxifen, anastrozole, zoledronic acid
- Where
- 72 sites in Austria, Germany
- Volunteers
- 1,803 people
- Sponsor
- Austrian Breast & Colorectal Cancer Study Group
Osteopenia
3-year Study of Menostar Versus Evista to Prevent Osteoporosis in Post-menopausal Women
The aim of this trial is to investigate whether the Menostar patch is as safe and effective in the prevention of bone loss in postmenopausal women as raloxifen, a drug already registered for prevention and treatment of…
- Trial name
- NCT00310531
- Testing
- Menostar (Estradiol, BAY86-5435), Raloxifene
- Volunteers
- 500 people
- Sponsor
- Bayer
Breast Cancer, Metastatic Disease
Evaluation of the Association Between CYP2D6 Genetic Polymorphisms and the Treatment Effect of Tamoxifen
Primary objectives of this study is to evaluate the effects of CYP2D6 genotypes on time to progression after tamoxifen treatment in pre- or postmenopausal women with metastatic breast cancer.
- Trial name
- NCT00532454
- Testing
- Tamoxifen
- Where
- 2 sites in South Korea
- Volunteers
- 21 people
- Sponsor
- National Cancer Center, Korea
Breast Cancer, Estrogen Receptor Positive Tumor
Characterization of Biophysical and Mechanical Parameters on Skin of Breast Cancer Patients
Aim of this study is to characterize the chemical/physical and structural parameters of the skin in patients with breast cancer undergoing oncological adjuvant treatment in order to understand how to prevent and manage adverse…
- Trial name
- NCT06474988
- Testing
- Skin tests
- Where
- Italy
- Volunteers
- 150 people
- Sponsor
- European Institute of Oncology
Breast Cancer
SU5416 and Doxorubicin in Treating Patients With Stage IIIB or Stage IV Inflammatory Breast Cancer
RATIONALE: SU5416 may stop the growth of breast cancer by stopping blood flow to the tumor. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00005822
- Testing
- doxorubicin hydrochloride, semaxanib, conventional surgery
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Case Comprehensive Cancer Center
Metastatic Breast Cancer
A Randomized, Open-label, Multi-center Phase IV Study Evaluating Palbociclib Plus Endocrine Treatment Versus a Chemotherapy-based Treatment Strategy in Patients With Hormone Receptor Positive / HER2 Negative Breast Cancer in a Real World Setting (GBG 93 - PADMA Study).
The goal of the study for patients with metastatic breast cancer (MBC) is to show that palbociclib + endocrine therapy shows a significant improvement in time-to-treatment failure over chemotherapy regimen (mono-chemotherapy with…
- Trial name
- PADMA (NCT03355157)
- Testing
- Palbociclib / Chemotherapy (capecitabine, epirubicin, paclitaxel, vinorelbine) / Endocrine therapy (exemestane, fulvestrant, letrozole, tamoxifen)
- Where
- Germany
- Volunteers
- 130 people
- Sponsor
- GBG Forschungs GmbH
Breast Diseases, Breast Neoplasms
Efficacy and Safety of Dalpiciclib Combined With Endocrine Adjuvant Therapy for Early HR +/HER2- Breast Cancer: a Multicenter, Prospective Clinical Study
This study is a multicenter, prospective, randomized, open-label clinical study to assess the efficacy and safety of endocrine combined with different doses and treatment duration of darisenatide adjuvant therapy in HR +/HER2…
- Conditions
- Breast Diseases, Breast Neoplasms, Dalpiciclib, Endocrine Breast Diseases
- Trial name
- NCT07581834
- Testing
- Dalpiciclib 125mg, Dalpiciclib 100mg, Endocrine Therapy (ET): letrozole, anastrozole, exemestane, tamoxifen
- Where
- 2 sites in China
- Volunteers
- 2,000 people
- Sponsor
- Fujian Cancer Hospital
Osteoporosis, Postmenopausal
Comparison of Raloxifene Hydrochloride and Placebo in the Treatment of Postmenopausal Women With Osteoporosis
To study the effect of long-term treatment with raloxifene, compared with placebo, on the rate of new vertebral fractures in osteoporotic postmenopausal women with and without existing vertebral fractures.
- Trial name
- MORE (NCT00670319)
- Testing
- Raloxifene HCL
- Where
- 25 sites in United States, Argentina and 23 more
- Volunteers
- 7,705 people
- Sponsor
- Eli Lilly and Company
Breast Cancer
SWOG-8814 Tamoxifen With or Without Combination Chemotherapy in Postmenopausal Women Who Have Undergone Surgery for Breast Cancer
RATIONALE: Estrogen can cause the growth of breast cancer cells. Hormone therapy using tamoxifen may fight breast cancer by blocking the use of estrogen by the tumor cells.
- Trial name
- NCT00929591
- Testing
- cyclophosphamide, doxorubicin hydrochloride, endocrine therapy
- Volunteers
- 1,558 people
- Sponsor
- SWOG Cancer Research Network
Sleep Disorder, Breast Cancer
Sleep and Activity Patterns in Pre-menopausal Breast Cancer Patients on Tamoxifen Using a Wrist-worn Internet of Things Device
The aim of this study is to observe the sleep and activity patterns of pre-menopausal breast cancer patients taking tamoxifen using a wrist-worn internet of things device and questionnaires.
- Trial name
- NCT04116827
- Testing
- Tamoxifen Oral Tablet
- Where
- South Korea
- Volunteers
- 20 people
- Sponsor
- Samsung Medical Center
Breast Cancer, Endometrial Cancer
Endometrial Changes in Breast Cancer Women With or Without Hormonal Therapies
A history of breast cancer is a risk factor for the development of endometrial pathologies, such as typical and atypical glandular hyperplasia, endometrial polyps, uterine fibroids, endometrial adenocarcinoma and uterine sarcoma…
- Trial name
- BETA-1 (NCT03898947)
- Testing
- Diagnostic hysteroscopy and targeted endometrial biopsy
- Volunteers
- 1,329 people
- Sponsor
- Università degli Studi dell'Insubria
Breast Cancer
Evaluation of the Efficacy of Estramustine in Patient With Breast Cancer Progression After Treatment With Aromatase Inhibitor.
Despite advances in early detection and treatment strategy, about 25 to 40% of patients treated for breast cancer develop metastasis. Some patients are in a therapeutic impasse situation.
- Trial name
- EFESE (NCT02866955)
- Testing
- Estramustine, Tamoxifen
- Where
- 21 sites in France
- Volunteers
- 100 people
- Sponsor
- Institut de Cancérologie de Lorraine
Advanced Metastatic Breast Cancer
Study of Efficacy and Safety in Premenopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer
The purpose of this study was to determine whether treatment with tamoxifen or a non-steroidal aromatase inhibitors (NSAI) + goserelin + LEE011 prolonged progression-free survival (PFS) compared to treatment with tamoxifen or a…
- Trial name
- MONALEESA-7 (NCT02278120)
- Testing
- Ribociclib, Tamoxifen, Letrozole
- Where
- 183 sites in United States, Argentina and 28 more
- Volunteers
- 672 people
- Sponsor
- Novartis Pharmaceuticals
Breast Cancer
Trastuzumab Combined With Chemotherapy or Endocrine Therapy to Treat Metastatic Luminal B2 Breast Cancer
The primary objective of this study is to compare progression-free survival (PFS) of patients with metastatic Luminal B2 breast cancer subtype randomised to treatment with Trastuzumab Combined With Chemotherapy or Endocrine…
- Trial name
- SYSUCC-002 (NCT01950182)
- Testing
- Endocrine therapy combined with trastuzumab, Chemotherapy combined with trastuzumab
- Where
- China
- Volunteers
- 392 people
- Sponsor
- Sun Yat-sen University